Open Access Articles- Top Results for Lorvotuzumab mertansine

Lorvotuzumab mertansine

Lorvotuzumab mertansine?
File:Mertansine mab structure.svg
Monoclonal antibody
Type Whole antibody
Source Humanized
Target CD56
Clinical data
1008106-64-6 7pxN
KEGG D09927 7pxN
Chemical data
 14pxN (what is this?)  (verify)

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate. It comprises the CD56-binding antibody, lorvotuzumab (huN901), with the maytansinoid cell-killing agent, DM1, attached using the disulfide linker, SPP. (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine.)

Lorvotuzumab mertansine is an experimental agent created for the treatment of CD56 positive cancers(e.g. small-cell lung cancer, ovarian cancer).[1][2]

It has been granted Orphan drug status for Merkel cell carcinoma.[3]

It has reported encouraging Phase II results for small-cell lung cancer.[4]


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.